Protavio took part in the European Association for Cancer Research Annual Congress (EACR 2025), held 16–19 June in Lisbon, Portugal, where leading scientists gathered to discuss advances in basic, pre‑clinical, and translational oncology. At our exhibitor stand we met cancer researchers and clinicians from across the globe and demonstrated how Protavio’s high‑throughput multiplex proteomics platform transforms complex protein data into actionable insights that accelerate biomarker discovery and precision diagnostics.
During the poster sessions we presented “Novel blood‑based protein biomarker signature for early detection of colorectal cancer and advanced adenomas,” featuring recent results from the Horizon Europe‑funded DIOPTRA project. Colorectal cancer (CRC) remains the second‑leading cause of cancer‑related deaths in Europe and the United States, but detecting it early raises the five‑year survival rate to more than 90 percent. While traditional colonoscopy remains the screening gold standard, its invasiveness discourages many eligible individuals from participating. Our poster outlined a blood-based biomarker panel for early detection, broadening screening uptake without compromising diagnostic performance.
Using a rigorous biomarker discovery workflow, Protavio identified a panel of blood proteins mechanistically linked to CRC. In the initial pilot cohort, the signature achieved sensitivity and specificity above 90% for stage I–II cancers and demonstrated strong detection of precancerous advanced adenomas. These findings suggest that routine blood checks could soon help clinicians intercept both malignancies and high-risk lesions at far earlier, more treatable stages.
The project is now scaling to a multi‑centre validation study across Europe to confirm performance in a larger, more diverse population. Meanwhile, Protavio is converting the discovery read‑out into a high‑throughput multiplex immunoassay ready for clinical workflows.
We are grateful to everyone who visited our stand and poster session to discuss the future of translational cancer research and patient‑centred care. Your insights and collaborations drive us to keep pushing the boundaries of proteomics.